

**Amendments to the Claims:**


Please amend claims 8, 12, 13, 14, 15 and 16.

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.-7. (Cancelled)

8. (Currently Amended) A method for inhibiting LPAAT- $\beta$  (lysophosphatidic acid acyltransferase  $\beta$ ) comprising contacting LPAAT- $\beta$  with an effective amount of a compound of the Formula:



wherein,

R<sup>1</sup> is halo, hydroxy, alkylmercapto, mercapto, alkoxy, aryloxy or substituted amino;

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup>, each of which may be same or different, are hydrogen, alkyl, substituted alkyl, alkenyl, alkynyl, aryl or substituted aryl; or

R<sup>2</sup> and R<sup>3</sup> or R<sup>4</sup> and R<sup>5</sup>, together with the nitrogen to which they are attached, form a piperidine, piperazine, or a morpholine ring; or

pharmaceutically acceptable salts thereof;

thereby inhibiting LPAAT- $\beta$ .

9. (Original) The method of claim 8, wherein said LPAAT- $\beta$  is found in an animal.
10. (Original) The method of claim 9, wherein said animal is a mammal.
11. (Original) The method of claim 10, wherein said mammal is a human.
12. (Currently Amended) The method of claim 8, wherein R<sup>1</sup> is chloro, R<sup>2</sup> and R<sup>4</sup> are hydrogen and R<sup>3</sup> and R<sup>5</sup> are phenyl; or  
pharmaceutically acceptable salts salt thereof.
13. (Currently Amended) The method of claim 8, wherein R<sup>1</sup> is chloro, R<sup>2</sup> and R<sup>4</sup> are hydrogen, R<sup>3</sup> is phenyl and R<sup>5</sup> is 4-chlorophenyl; or  
pharmaceutically acceptable salts salt thereof.
14. (Currently Amended) The method of claim 8, wherein R<sup>1</sup> is chloro, R<sup>2</sup> and R<sup>4</sup> are hydrogen, R<sup>3</sup> is t-butyl and R<sup>5</sup> is 4-chlorophenyl; or  
pharmaceutically acceptable salts salt thereof.
15. (Currently Amended) The method of claim 8, wherein R<sup>1</sup> is chloro, R<sup>2</sup> and R<sup>4</sup> are hydrogen, R<sup>3</sup> is 4-methoxyphenyl and R<sup>5</sup> is 4-chlorophenyl; or  
pharmaceutically acceptable salts salt thereof.
16. (Currently Amended) The method of claim 8, wherein the compound is selected from the group consisting of 6-chloro-N-(4-methoxy-phenyl)-N'-p-tolyl-[1,3,5]triazine-2,4-diamine, N-butyl-6-chloro-N'-(4-chlorophenyl)-[1,3,5]triazine-2,4-diamine, 6-chloro-N-isopropyl-N'-p-tolyl-[1,3,5]triazine-2,4-diamine, N-tert-butyl-6-chloro-N'-phenyl-[1,3,5]triazine-2,4-diamine, (4-chloro-6-morpholin-4-yl-[1,3,5]triazin-2-yl)-naphthalen-1-yl-amine, N-tert-butyl-6-chloro-N'-p-tolyl-[1,3,5]triazine-2,4-diamine, 6-chloro-N-cyclo-hexyl-N'-isopropyl-

[1,3,5]triazine-2,4-diamine, 2-(4-chloro-6-phenylamino-[1,3,5]triazin-2-ylamino)-2-methylpropan-1-ol, 6-chloro-N-isopropyl-N'-phenyl-[1,3,5]triazine-2,4-diamine, 6-chloro-N-(4-chlorophenyl)-N'-cyclohexyl-[1,3,5]triazine-2,4-diamine, N-allyl-6-chloro-N'-cyclohexyl-[1,3,5]triazine-2,4-diamine, 2-(4-chloro-6-phenylamino-[1,3,5]triazin-2-ylamino)-ethanol, N-tert-butyl-6-chloro-N'-cyclopentyl-[1,3,5]triazine-2,4-diamine, 6-chloro-N-(4-methoxyphenyl)-N'-phenyl-[1,3,5]triazine-2,4-diamine, N-benzo[1,3]dioxol-5-yl-6-chloro-N'-(4-chlorophenyl)-[1,3,5]triazine-2,4-diamine, 6-chloro-N-(2,3-dihydrobenzo[1,4]dioxin-6-yl)-N'-phenyl-[1,3,5]triazine-2,4-diamine, 6-chloro-N-indan-5-yl-N'-phenyl-[1,3,5]triazine-2,4-diamine, 6-chloro-N-(4-chlorophenyl)-N'-propyl-[1,3,5]triazine-2,4-diamine, N-(4-chloro-phenyl)-6-methoxy-N'-propyl-[1,3,5]triazine-2,4-diamine and N-(4-chloro-phenyl)-6-methylsulfanylmethylmercapto-N'-phenyl-[1,3,5]triazine-2,4-diamine.

17.-39. (Cancelled)